Company Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Country | United States |
Founded | 2015 |
IPO Date | Aug 21, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 187 |
CEO | Dr. Nello Mainolfi M.D., Ph.D. |
Contact Details
Address: 500 North Beacon Street, 4th Floor Watertown, Massachusetts 02472 United States | |
Phone | 857-285-5314 |
Website | kymeratx.com |
Stock Details
Ticker Symbol | KYMR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $20.00 |
CIK Code | 0001815442 |
CUSIP Number | 501575104 |
ISIN Number | US5015751044 |
Employer ID | 81-2992166 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Bruce L. Booth DPHIL, Ph.D. | Co-Founder and Chairman |
Dr. Nello Mainolfi M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
Bruce N. Jacobs CFA | Chief Financial Officer |
Dr. Jared A. Gollob M.D. | Chief Medical Officer |
Dr. Jeremy G. Chadwick Ph.D. | Chief Operating Officer |
Ellen V. Chiniara Esq., J.D. | Chief Legal Officer and Corporate Secretary |
Karen Weisbach | Head of People and Culture |
Dr. Juliet Williams B.A Ph.D. | Head of Research |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 1, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
Apr 1, 2024 | 8-K | Current Report |
Mar 15, 2024 | 144 | Filing |
Mar 15, 2024 | 144 | Filing |
Mar 14, 2024 | 144 | Filing |
Mar 14, 2024 | 144 | Filing |
Mar 13, 2024 | 144 | Filing |
Mar 13, 2024 | 144 | Filing |
Mar 12, 2024 | 144 | Filing |
Mar 12, 2024 | 144 | Filing |